THERAPY DOSSIER · th-f2abc33b1a7f

Aspirin, with indomethacin and the selective COX-2 inhibitor SC-236 also tested

Drug · Cyclooxygenase inhibitor (INHIBITOR, direct interaction, disease efficacy true). ATC B01AC06, N02BA01, A01AD05.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Cyclooxygenase inhibitor (INHIBITOR, direct interaction, disease efficacy true). ATC B01AC06, N02BA01, A01AD05.
Target: CHEMBL2094253
Injury models: Fracture
Reported indication: Analgesic/antipyretic/anti-inflammatory and antiplatelet agent (secondary prevention of MI/stroke); long-standing approval
First approval: 1950
Development stage: Approved analgesic/antiplatelet; acute lung injury prevention not established (LIPS-A negative)
ChEMBL record: CHEMBL25 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Acetylsalicylic acid; Acetylsalicylate; Aspirin; Salicylic acid acetate; Durlaza; Vazalore
Note: Not recorded

Clinical trials 4

3 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02901067 ↗Injury indicationPHASE2terminated

STAT: statins and aspirin in trauma, reduction of acute lung injury and VTE in fibrinolysis shutdown

Wounds and Injuries · Venous Thromboembolism

Enrolment: 43 · Results not recorded

NCT01659307 ↗Injury indicationPHASE2completed

Effect of aspirin on reducing inflammation in a human in vivo model of acute lung injury

Acute Lung Injury

Enrolment: 33 · Results not recorded

NCT00494156 ↗Injury indicationNAwithdrawn

Anticoagulation in the management of grade I-III blunt cerebrovascular injuries

Carotid Artery Injury · Vertebral Artery Injury

Enrolment: 0 · Results not recorded

NCT06512233 ↗NAunknown

Heparin alone vs heparin-aspirin combination in free flap survival

Postoperative Complication

Enrolment: 126 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23871514 ↗2013Mixed findings

Monitoring tissue inflammation and responses to drug treatments in early stages of mice bone fracture using 50 MHz ultrasound.

MouseFractureTibiaC57BL/6N (B6)femalen = 18 mice in total, with data from three independent animals…oralaspirin 100 to 400 mg/kg/day; indomethacin 1.5 to 2 mg/kg/d…started after the fracture was produced

Model: Closed mid-shaft tibial fracture stabilised with a 0.20 mm intramedullary steel pin, produced with a free-dropping impact injury simulator under chloral hydrate anaesthesia and confirmed by X-ray

Aspirin significantly reduced fracture-induced hyperechogenicity, with day 7 echogenicity of 1.14 plus or minus 0.29 fold versus 1.71 plus or minus 0.21 fold in untreated fractured mice, and also inhibited cell death and COX-2 and BLT1 expression. Indomethacin and SC-236 did not reduce hyperechogen…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…